Dahai Yu

Dr. Dahai Yu


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
RQRui Qin
Rui Qin
TCTao Chen
Tao Chen
QLQingqing Lou
Qingqing Lou
DYDahai Yu
Dahai Yu

1 August 2008 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
DHDongsheng Hu
Dongsheng Hu
PFPengyu Fu
Pengyu Fu
JXJing Xie
Jing Xie
CCChung-Shiuan Chen
Chung-Shiuan Chen
DYDahai Yu
Dahai Yu
DGDongfeng Gu
Dongfeng Gu

9 July 2015 in Rheumatology
Verified
Journal Article
Open access
PDF file
DYDahai Yu
Dahai Yu
GPGeorge Peat
George Peat
JBJohn Bedson
John Bedson
KJKelvin P. Jordan
Kelvin P. Jordan
Objectives. To estimate the consultation incidence of OA using population-based health care data in England and compare OA incidence figures with those derived in other countries. Methods. A population-based health care database (Consultations in Primary Care Archive) in England was used to derive the consultation incidence of OA (overall and by joint site) using the maximum available run-in period method. These estimates, and their distribution by age and sex, were compared with those published from population-based health care databases in Canada, the Netherlands and Spain. A novel age-stratified run-in period method was then used to investigate whether the consultation incidence has been increasing over time in younger adults. Results. The annual consultation incidence of OA (any joint) was 8.6/1000 persons ≥15 years of age (95% CI 7.9, 9.3) [6.3 (95% CI 5.5, 7.1) in men and 10.8 (95% CI 9.8, 12.0) in women]. Incidence increased sharply between 45 and 64 years of age, peaking at 75–84 years. The joint-specific incidence was 1.4 (95% CI 1.1, 1.7), 3.5 (95% CI 3.1, 3.9) and 1.3 (95% CI 1.1, 1.6) for hip OA, knee OA and hand OA, respectively. The estimates and their distribution by age and sex were broadly consistent with international estimates. Between 2003 and 2010, incidence in those aged 35–44 years increased from 0.3 to 2.0/1000 persons. Conclusion. Newly diagnosed cases of OA in England occur in 9 in 1000 at-risk adults each year, similar to other international estimates. Although lower, the consultation incidence proportion in younger adults appears to have increased in the past decade.

4 August 2017 in Rheumatology
Verified
Journal Article
Open access
PDF file
DYDahai Yu
Dahai Yu
KJKelvin P Jordan
Kelvin P Jordan
JBJohn Bedson
John Bedson
MEMartin Englund
Martin Englund
FBFiona Blyth
Fiona Blyth
GPGeorge Peat
George Peat
To determine recent trends in the rate and management of new cases of OA presenting to primary healthcare using UK nationally representative data. Using the Clinical Practice Research Datalink we identified new cases of diagnosed OA and clinical OA (including OA-relevant peripheral joint pain in those aged over 45 years) using established code lists. For both definitions we estimated annual incidence density using exact person-time, and undertook descriptive analysis and age-period-cohort modelling. Demographic characteristics and management were described for incident cases in each calendar year. Sensitivity analyses explored the robustness of the findings to key assumptions. Between 1992 and 2013 the annual age-sex standardized incidence rate for clinical OA increased from 29.2 to 40.5/1000 person-years. After controlling for period effects, the consultation incidence of clinical OA was higher for successive cohorts born after the mid-1950s, particularly women. In contrast, with the exception of hand OA, we observed no increase in the incidence of diagnosed OA: 8.6/1000 person-years in 2004 down to 6.3 in 2013. In 2013, 16.4% of clinical OA cases had an X-ray referral. While NSAID prescriptions fell from 2004, the proportion prescribed opioid analgesia rose markedly (0.1% of diagnosed OA in 1992 to 1.9% in 2013). Rising rates of clinical OA, continued use of plain radiography and a shift towards opioid analgesic prescription are concerning. Our findings support the search for policies to tackle this common problem that promote joint pain prevention while avoiding excessive and inappropriate health care.

1 October 2012 in Environmental Health Perspectives
Verified
Journal Article
Open access
RARichard W. Atkinson
Richard W. Atkinson
DYDahai Yu
Dahai Yu
BABen G. Armstrong
Ben G. Armstrong
SPSam Pattenden
Sam Pattenden
PWPaul Wilkinson
Paul Wilkinson
HAH. Ross Anderson
H. Ross Anderson
Background: Short-term exposure to ozone has been associated with increased daily mortality. The shape of the concentration–response relationship—and, in particular, if there is a threshold—is critical for estimating public health impacts.Objective: We investigated the concentration–response relationship between daily ozone and mortality in five urban and five rural areas in the United Kingdom from 1993 to 2006.Methods: We used Poisson regression, controlling for seasonality, temperature, and influenza, to investigate associations between daily maximum 8-hr ozone and daily all-cause mortality, assuming linear, linear-threshold, and spline models for all-year and season-specific periods. We examined sensitivity to adjustment for particles (urban areas only) and alternative temperature metrics.Results: In all-year analyses, we found clear evidence for a threshold in the concentration–response relationship between ozone and all-cause mortality in London at 65 µg/m3 [95% confidence interval (CI): 58, 83] but ...

22 July 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
DYDahai Yu
Dahai Yu
ZWZheng Wang
Zheng Wang
XZXiaoxue Zhang
Xiaoxue Zhang
BQBingjie Qu
Bingjie Qu
YCYamei Cai
Yamei Cai
David SimmonsDavid Simmons
David Simmons
Context: The association between remnant cholesterol (remnant-C) and cardiovascular mortality in patients with type 2 diabetes (T2D) and incident diabetic nephropathy remains unclear. Objective: To examinie the association between remnant-C and cardiovascular mortality in patients with T2D, chronic kidney disease (CKD) stages 3 to 5, and newly diagnosed DN. Methods: This study determined the baseline lipid profile and searched for deaths with cardiovascular disease (CVD) within 2 years of baseline among 2282 adults enrolled between January 1, 2015 and December 31, 2016, who had T2D, CKD stages 3 to 5, and newly diagnosed DN. Adjusted logistic regression models were used to assess the associations between lipid, especially remnant-C concentration (either as continuous or categorical variables), and risk of cardiovascular mortality. Results: In multivariable-adjusted analyses, low-density lipoprotein cholesterol (LDL-C) (odds ratio [OR], 1.022; 95% CI, 1.017-1.026, per 10 mg/dL), high-density lipoprotein cholesterol (HDL-C) (OR, 0.929; 95% CI, 0.922-0.936, per 5 mg/dL), non–HDL-C (OR, 1.024; 95% CI, 1.021-1.028, per 10 mg/dL), and remnant-C (OR, 1.115; 95% CI, 1.103-1.127, per 10 mg/dL), but not triglycerides were associated with cardiovascular mortality. Atherogenic dyslipidemia (triglycerides > 150 mg/dL [1.69 mmol/L] and HDL-C < 40 mg/dL in men or < 50 mg/dL in women) was also associated with cardiovascular mortality (OR, 1.073; 95% CI, 1.031-1.116). Remnant-C greater than or equal to 30 mg/dL differentiated patients at a higher risk of cardiovascular mortality from those with lower concentrations, especially with interaction with LDL-C level greater than 100 mg/dL: The highest risk was found in patients with higher levels both of remnant-C and LDL-C (OR, 1.696; 95% CI, 1.613-1.783). Conclusion: In patients with T2D, CKD stages 3 to 5, and incident DN, remnant-C was associated with a higher risk of death with CVD. Different from the general population, the interaction of remnant-C and LDL-C was associated with the highest risk of cardiovascular mortality.